

A practical guide for providers: help your patients find Epipen in stock with 5 actionable steps, alternative options, and workflow tips for your practice.
As a prescriber, you've likely heard the frustration firsthand: a parent calls your office because their child's Epipen expired and no pharmacy in town has it. A patient with a severe bee sting allergy reports they've been without an auto-injector for weeks. A new diagnosis leaves a patient anxious — and unable to fill the prescription you just wrote.
Epinephrine auto-injector access has improved since the worst of the 2018-2019 shortage, but the problem hasn't disappeared. Patients continue to encounter stockouts, particularly during seasonal demand peaks and in certain regions. As their provider, you're often the first person they turn to for help.
This guide provides a practical framework for helping your patients locate Epipen (or an equivalent epinephrine auto-injector) when their pharmacy comes up empty — along with workflow tips to reduce the burden on your practice.
In 2026, the epinephrine auto-injector market includes more products than ever:
Despite multiple options, patients often don't know about alternatives — or they assume their prescription is limited to the specific brand you wrote. Provider guidance is essential.
Understanding the root causes helps you counsel patients more effectively:
When clinically appropriate, prescribe "epinephrine auto-injector" rather than a specific brand. This empowers pharmacists to dispense whichever FDA-approved product is in stock — whether that's brand Epipen, the authorized generic, Auvi-Q, or Adrenaclick.
If your state requires device-specific prescriptions for substitution, consider writing multiple prescriptions (one for Epipen, one for Auvi-Q) so the pharmacist can fill whichever is available.
Medfinder for Providers allows you and your patients to search for epinephrine auto-injector availability at nearby pharmacies in real time. Consider:
This can reduce the number of callback requests your office receives about availability issues.
Many patients believe Epipen is their only option because it's the brand they know. Take 60 seconds during the prescribing conversation to mention:
Keep trainer devices for multiple products in your office so patients can practice before leaving.
Cost is a hidden driver of the availability problem — patients who can't afford to fill their prescription may delay until it becomes urgent, or they may go without entirely. Proactively share cost-saving options:
A printed handout with this information can save your staff from fielding repeated cost-related calls. Direct patients to our comprehensive guide on saving money on Epipen.
Encourage patients to refill 4-6 weeks before expiration — not the week of. Consider adding expiration date tracking to your follow-up workflow:
Switching a patient from Epipen to an alternative is appropriate when:
When switching, always review the new device technique with the patient and update their anaphylaxis action plan. For patients with school-age children, remind families to update the action plan on file at school.
The Epipen availability challenge isn't going away overnight, but providers have more tools and options than ever to help patients stay protected. Flexible prescribing, proactive cost counseling, patient education about alternatives, and tools like Medfinder can make a meaningful difference in your patients' ability to access this life-saving medication.
No patient with anaphylaxis risk should be left without an epinephrine auto-injector. With a few workflow adjustments, your practice can be a reliable resource in an unreliable supply landscape.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.